Evidence map›Paper›PMID 26374678›Full record

ArticleClinical trials (London, England)2015

Harmonization and streamlining of research oversight for pragmatic clinical trials.

P Pearl O'Rourke, Judith Carrithers, Bray Patrick-Lake, Todd W Rice, Jeremy Corsmo, Raffaella Hart, Marc K Drezner, John D Lantos

Abstract read
In one paragraph

Article in Clinical trials (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Lessons Learned From a Practice-Based, Multisite Intervention Study With Nurse Participants.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2017
    Trial
  2. Article
  3. Review
  4. Article
  5. Pragmatic clinical trial design in emergency medicine: Study considerations and design types.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2022
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Pragmatic Trials in Maintenance Dialysis: Perspectives from the Kidney Health Initiative.Journal of the American Society of Nephrology : JASN · 2016
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 1 country.

P Pearl O'RourkeHuman Research Affairs, Partners HealthCare, Boston, MA, USA porourke@partners.org.
Judith CarrithersSchool of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Bray Patrick-LakeClinical Trials Transformation Initiative, Duke University, Durham, NC, USA.
Todd W RiceDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University, Nashville, TN, USA.
Jeremy CorsmoOffice of Research Compliance and Regulatory Affairs, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Raffaella HartBiomedical Research Alliance of New York, Lake Success, NY, USA.
Marc K DreznerSchool of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA.
John D LantosChildren's Mercy Bioethics Center, Children's Mercy Hospital, Kansas City, MO, USA.
Children's Mercy Hospital · USCincinnati Children's Hospital Medical Center · USDuke University · USJohns Hopkins Medicine · USMass General Brigham · USUniversity of Wisconsin–Madison · USVanderbilt University · US

Funding

Clinical Coordinating Center Network of Excellence in Neuroscience Clinical TrialU01NS077179 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI Merit E CUDKOWICZ, Aleksandar Videnovic · 2011 to 2026
$43.4M
Health Care Systems Research Collaboratory SupplementU54AT007748 · NCCIH · DUKE UNIVERSITY · PI CURTIS, LESLEY H, HERNANDEZ, ADRIAN · 2012 to 2017
$15.1M
Heartland Institute for Clinical and Translational ResearchUL1TR000001 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BAROHN, RICHARD J. · 2012 to 2015
$13.0M
HEARTLAND INSTITUTE FOR CLINICAL AND TRANSLATIONAL RESEARCHUL1RR033179 · NCRR · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BAROHN, RICHARD J. · 2011 to 2011
$3.2M
Using real world decisions to develop a modified central IRB modelR01HL126492 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICE, TODD W · 2014 to 2016
$1.2M
Novel IRB Models for Efficient Multi-Site Review: Planning Conference SeriesR13TR000052 · NCATS · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2012 to 2013
$57k
NCATS NIH HHS R13 TR000052NCATS NIH HHS UL1 TR000001NCCIH NIH HHS U54 AT007748NCRR NIH HHS UL1 RR033179NHLBI NIH HHS R01 HL126492NINDS NIH HHS U01 NS077179
6 · The paper itself

Abstract

The oversight of research involving human participants is a complex process that requires institutional review board review as well as multiple non-institutional review board institutional reviews. This multifaceted process is particularly challenging for multisite research when each site independently completes all required local reviews. The lack of inter-institutional standardization can result in different review outcomes for the same protocol, which can delay study operations from start-up to study completion. Hence, there have been strong calls to harmonize and thus streamline the research oversight process. Although the institutional review board is only one of the required reviews, it is often identified as the target for harmonization and streamlining. Data regarding variability in decision-making and interpretation of the regulations across institutional review boards have led to a perception that variability among institutional review boards is a primary contributor to the problems with review of multisite research. In response, many researchers and policymakers have proposed the use of a single institutional review board of record, also called a central institutional review board, as an important remedy. While this proposal has merit, the use of a central institutional review board for multisite research does not address the larger problem of completing non-institutional review board institutional review in addition to institutional review board review—and coordinating the interdependence of these reviews. In this article, we describe the overall research oversight process, distinguish between institutional review board and institutional responsibilities, and identify challenges and opportunities for harmonization and streamlining. We focus on procedural and organizational issues and presume that the protection of human subjects remains the paramount concern. Suggested modifications of institutional review board processes that focus on time, efficiency, and consistency of review must also address what effect such changes have on the quality of review. We acknowledge that assessment of quality is difficult in that quality metrics for institutional review board review remain elusive. At best, we may be able to assess the time it takes to review protocols and the consistency across institutions.

Indexed as

Biomedical ResearchClinical Trials as TopicDecision MakingEthics Committees, ResearchHumansResearch DesignUnited StatesCentral institutional review boardhuman research protection programinstitutional review boardspragmatic clinical trialsresearch oversight

Identifiers

PMID26374678
PMCPMC4592396
OpenAlexW2228475140

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.